216 related articles for article (PubMed ID: 21923736)
21. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.
Hambrock A; Löffler-Walz C; Quast U
Br J Pharmacol; 2002 Aug; 136(7):995-1004. PubMed ID: 12145099
[TBL] [Abstract][Full Text] [Related]
22. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
23. Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S; Takahashi H; Takahashi T; Shibasaki T
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
[TBL] [Abstract][Full Text] [Related]
24. The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.
Stephan D; Stauss E; Lange U; Felsch H; Löffler-Walz C; Hambrock A; Russ U; Quast U
Br J Pharmacol; 2005 Apr; 144(8):1078-88. PubMed ID: 15711591
[TBL] [Abstract][Full Text] [Related]
25. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
26. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner.
Hambrock A; de Oliveira Franz CB; Hiller S; Grenz A; Ackermann S; Schulze DU; Drews G; Osswald H
J Biol Chem; 2007 Feb; 282(5):3347-56. PubMed ID: 17138562
[TBL] [Abstract][Full Text] [Related]
27. Characterization of K(ATP)-channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression.
Jansen-Olesen I; Mortensen CH; El-Bariaki N; Ploug KB
Eur J Pharmacol; 2005 Oct; 523(1-3):109-18. PubMed ID: 16226739
[TBL] [Abstract][Full Text] [Related]
28. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.
Reimann F; Proks P; Ashcroft FM
Br J Pharmacol; 2001 Apr; 132(7):1542-8. PubMed ID: 11264248
[TBL] [Abstract][Full Text] [Related]
29. ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP.
Hambrock A; Löffler-Walz C; Kloor D; Delabar U; Horio Y; Kurachi Y; Quast U
Mol Pharmacol; 1999 May; 55(5):832-40. PubMed ID: 10220561
[TBL] [Abstract][Full Text] [Related]
30. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels.
Bryan J; Crane A; Vila-Carriles WH; Babenko AP; Aguilar-Bryan L
Curr Pharm Des; 2005; 11(21):2699-716. PubMed ID: 16101450
[TBL] [Abstract][Full Text] [Related]
31. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T).
Hambrock A; de Oliveira Franz CB; Hiller S; Osswald H
J Pharmacol Exp Ther; 2006 Mar; 316(3):1031-7. PubMed ID: 16306272
[TBL] [Abstract][Full Text] [Related]
32. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels.
Hu S; Wang S; Dunning BE
J Pharmacol Exp Ther; 1999 Dec; 291(3):1372-9. PubMed ID: 10565863
[TBL] [Abstract][Full Text] [Related]
33. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
Cui Y; Tinker A; Clapp LH
Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
[TBL] [Abstract][Full Text] [Related]
34. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
[TBL] [Abstract][Full Text] [Related]
35. Localization of sulfonylurea receptor subunits, SUR2A and SUR2B, in rat heart.
Zhou M; He HJ; Suzuki R; Liu KX; Tanaka O; Sekiguchi M; Itoh H; Kawahara K; Abe H
J Histochem Cytochem; 2007 Aug; 55(8):795-804. PubMed ID: 17438353
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels.
Liu Y; Ren G; O'Rourke B; Marbán E; Seharaseyon J
Mol Pharmacol; 2001 Feb; 59(2):225-30. PubMed ID: 11160857
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Malaisse WJ
Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
[TBL] [Abstract][Full Text] [Related]
38. Transgenic overexpression of SUR1 in the heart suppresses sarcolemmal K(ATP).
Flagg TP; Remedi MS; Masia R; Gomes J; McLerie M; Lopatin AN; Nichols CG
J Mol Cell Cardiol; 2005 Oct; 39(4):647-56. PubMed ID: 16099470
[TBL] [Abstract][Full Text] [Related]
39. Molecular basis and characteristics of KATP channel in human corporal smooth muscle cells.
Insuk SO; Chae MR; Choi JW; Yang DK; Sim JH; Lee SW
Int J Impot Res; 2003 Aug; 15(4):258-66. PubMed ID: 12934053
[TBL] [Abstract][Full Text] [Related]
40. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.
Song DK; Ashcroft FM
Br J Pharmacol; 2001 May; 133(1):193-9. PubMed ID: 11325810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
